Songdo Bio Campus Plant 1

Expanding global biopharmaceutical production requires advanced facility design and a reliable, high-performing manufacturing network. This brochure introduces a state-of-the-art, cGMP-ready facility engineered to streamline technology transfers and scale production from early clinical phases to commercial supply. Utilizing a multi-floor gravity flow design, the plant integrates specialized cell culture systems—including a unique quad-bioreactor setup —with flexible production options that support a two-day manufacturing cadence.

The site boasts a total capacity of 120kL, leveraging large-scale bioreactors equipped with real-time monitoring and advanced scaling strategies to ensure predictable process development. Operating across a dual-site model with facilities in both the United States and South Korea, the organization combines global CDMO expertise with a highly cross-trained workforce. Operational metrics highlight a 98% batch success rate and zero critical regulatory inspection observations. Backed by automated data sharing and dedicated project management, the facility delivers rapid timelines—such as achieving IND readiness within 10 months —while maintaining strong cost-competitiveness through economies of scale.